SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2003
ORPHAN MEDICAL, INC.
--------------------
(Exact name of registrant as specified in its charter)
Delaware 0-24760 41-1784594
-------- ------- ----------
(State or other jurisdiction (Commission (I.R.S. employer
of incorporation) file number) identification number)
Suite 250,
13911 Ridgedale Drive,
Minnetonka, MN 55305 (952) 513-6900
-------------- ----- --------------
(Address of principal (zip code) (Registrant's telephone
executive offices) number, including
area code)
Not Applicable
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events.
-------------
The Company announced a licensing agreement with Celltech Pharmaceuticals, a
division of Celltech Group plc, for the sales and marketing rights for Xyrem(R)
(sodium oxybate) oral solution in Europe. The Company received $2.5 million of
initial proceeds from the transaction. This agreement was discussed in the
Company's press release dated October 30, 2003. The press release is attached as
Exhibit 99.1 to this Form 8-K.
Item 7. Financial Statements and Exhibits
---------------------------------
Exhibit 99.1 - Press release dated October 30, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: October 31, 2003 ORPHAN MEDICAL, INC.
/s/ Timothy G. McGrath
-------------------------------------
Timothy G. McGrath
Chief Financial Officer
(duly authorized officer and
principal financial officer)
EXHIBIT INDEX
Exhibit
Number Description
99.1 Press release dated October 30, 2003.